127285-54-5

Usage

Uses

As the properties and potential applications of 6,7-Dimethoxy-3H-quinolin-4-one are still largely unknown, it is difficult to provide specific applications for 6,7-Dimethoxy-3H-quinolin-4-one. However, based on its chemical structure and the general properties of quinolinones, it can be speculated that it may have potential uses in various fields such as:
Used in Pharmaceutical Industry:
6,7-Dimethoxy-3H-quinolin-4-one could be used as a starting material or intermediate in the synthesis of pharmaceutical compounds, given its quinolinone core and methoxy functional groups. The presence of these functional groups may allow for further chemical modifications to enhance its biological activity or improve its pharmacokinetic properties.
Used in Chemical Research:
6,7-Dimethoxy-3H-quinolin-4-one may be used as a research compound in the field of organic chemistry, particularly in the study of quinolinone derivatives and their potential applications. Its synthesis, reactivity, and properties could be of interest to researchers working on the development of new synthetic methods or exploring the structure-activity relationships of quinolinone-based compounds.
Used in Material Science:
Although not extensively studied, 6,7-Dimethoxy-3H-quinolin-4-one may have potential applications in the field of material science, particularly in the development of new organic materials with unique properties. Its heterocyclic aromatic structure and methoxy functional groups could contribute to the formation of novel materials with potential uses in areas such as electronics, optics, or catalysis.

InChI:InChI=1/C11H11NO3/c1-14-10-5-7-8(6-11(10)15-2)12-4-3-9(7)13/h4-6H,3H2,1-2H3

Upstream product

• 4101-30-8 2-amino-4,5-dimethoxyacetophenone 
• 109-94-4 formic acid ethyl ester 
• 4101-32-0 4',5'-dimethoxy-2'-nitroacetophenone 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 127172-22-9 (E)-3-(N,N-dimethylamino)-1-(3,4-dimethoxyphenyl)-2-propen-1-one 
• 6315-89-5 3,4-dimethoxyaniline 
• 13436-14-1 ethyl 6,7-dimethoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylate 
• 26717-39-5 [[(3,4-Dimethoxyphenyl)amino]methylene]malonic acid,diethyl ester 
• 213699-53-7 5-(((3,4-dimethoxyphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 26893-22-1 1,4-Dihydro-6,7-dimethoxy-4-oxo-3-quinolinecarboxylic acid 

Downstream Products

• 347151-53-5 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester 
• 190728-25-7 4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline 
• 127285-64-7 6,7-dimethoxy-1-(4-methoxybenzyl)-4(1H)-quinolone 
• 228559-41-9 Ki 8751 

Relevant academic research and scientific papers

Novel substituted pyrazolo [1, 5-a] pyrimidine compound and preparation method and application thereof

The invention provides a novel substituted pyrazolo [1, 5-a]pyrimidine compound and a preparation method and application thereof, and particularly relates to a pyrazolo [1, 5-a]pyrimidine-containing quinoline derivative shown as a general formula (I) and pharmaceutically acceptable salts thereof, and substituent groups X, Ar and A have meanings given in the specification. The invention also relates to a compound represented by the general formula (I), wherein the compound has a strong c-Met kinase inhibition effect. The invention also relates to application of the compound and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing diseases caused by abnormal high expression of c-Met kinase, especially application in preparation of drugs for treating and/or preventing cancers.

BIHETEROCYCLIC COMPOUND

The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X═Y—Z, X—Y═Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

Co(III)-Catalyzed Enaminone-Directed C-H Amidation for Quinolone Synthesis

We report herein the development of a Co(III)-catalyzed enaminone-directed C-H amidation method for synthetic access to quinolones, an important heterocyclic scaffold for diverse pharmaceutically active structures. The C-H coupling with dioxazolones and subsequent deacylation of an installed amide group allow consecutive C-N coupling generation of quinolones with wide-ranging compatible substituent patterns.

2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application

The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.

Formation of fluorine-18 labeled diaryl ureas-labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis

Urea subunits are common components of various pharmaceuticals' core structure. Since in most cases the design and development of PET biomarkers is based on approved or potential drugs, there is a growing need for a general labeling methodology of urea-containing pharmacophores. As a part of research in the field of molecular imaging of angiogenic processes, we synthesized several highly potent VEGFR-2/PDGFR dual inhibitors as potential PET biomarkers. The structure of these inhibitors is based on the N-phenyl-N′-{4-(4-quinolyloxy)phenyl}urea skeleton. A representative inhibitor was successfully labeled with fluorine-18 by a three-step process. Initially, a two-step radiosynthesis of 4-[18F]fluoro-aniline from 1,4-dinitrobenzene (60 min, EOB decay corrected yield: 63%) was performed. At the third and final step, the 4-[18F]fluoro-aniline synthon reacted for 30 min at room temperature with 4-(2-fluoro-4-isocyanato-phenoxy)-6,7-dimethoxy-quinoline to give complete conversion of the labeled synthon to 1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-3-(4-[18F]fluoro-phenyl)-urea. The desired labeled product was obtained after total radiosynthesis time of 3 h including HPLC purification with 46 ± 1% EOB decay corrected radiochemical yield, 99% radiochemical purity, 99% chemical purity, and a specific activity of 400 ± 37 GBq/mmol (n = 5).

Met kinase inhibitors

The present invention is directed to compounds that are useful for treating cancer having one of the following Formulas:

Identification of potent and selective inhibitors of PDGF receptor autophosphorylation

We report the structure-activity relationship of quinoline and quinazoline derivatives, which include urea, thiourea, urethane, and acylthiourea groups, as inhibitors of the platelet-derived growth factor (PDGF) receptor autophosphorylation. Our previous studies showed that the quinoline and quinazoline derivatives including urea, thiourea, and carbamate groups were highly potent compounds as the PDGF receptor autophosphorylation inhibitor, but these compounds did not exhibit receptor selectivity between the PDGF receptor and the c-kit receptor. As a result of further synthesis and biological evaluation, we have found that the quinoline and quinazoline-acylthiourea derivatives showed not only good inhibitory activity for the PDGF receptor but also receptor selectivity between the PDGF receptor and the c-kit receptor. Furthermore N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(2- methylbenzoyl)thiourea exhibited potent oral efficacy in in vivo assay using the rat carotid balloon injury model. Therefore, the quinoline and quinazoline-acylthiourea derivatives may be expected to have potential as therapeutic agents for the treatment of restenosis.

Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: Synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-{4-(4-quinolyloxy)phenyl}ureas

N-Phenyl-N′-{4-(4-quinolyloxy)phenyl}ureas were found to be a novel class of potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase through synthetic modifications of a lead compound and structure-activity relationship studies. A representative compound 6ab, termed Ki8751, inhibited VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibited the PDGFR family members such as PDGFRα and c-Kit at 67 nM and 40 nM, respectively. However, 6ab did not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM. 6ab suppressed the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level. 6ab showed significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also showed complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body weight loss.

N-[2-CHLORO-4-(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM

The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-m ethyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.